Augustine Therapeutics

Augustine Therapeutics is proud to be sponsoring and participating to the iPSC Modelling in Neuromuscular Disorders (iMND) conference from October 23-25 in Leuven. This conference aims to unite scientists from academia as well as industry who use iPSC-derived models to obtain new insights into various motor neuron diseases. With the support of the US The ALS Association patient advocacy group, Augustine Therapeutic is currently advancing novel and best-in-class, brain penetrant and orally bioavailable selective HDAC6 inhibitors for the potential treatment of motor neuron diseases like Amyotrophic Lateral Sclerosis (ALS) Find out details of the event and agenda here: iPSC Modelling in Neuromuscular Disorders (iMND) | VIB Conferences VIB VIB-KU Leuven Center For Brain & Disease Research #research #drugdiscovery #iMND

We are excited to welcome our new Discovery team member Dr. Tugsan Tezil, Principal Scientist in the Pharmacology Department. With extensive international experience spanning Turkey, Italy, Hungary, the United States and Belgium, Tugsan Tezil is a distinguished molecular biologist and geneticist. His research journey began with pioneering studies on the blood-brain barrier and ion channels in sensory neurons. During his Ph.D. at Sabanci University and the IRCCS Centro di Riferimento Oncologico, Italy, he focused on small molecules in cancer therapy. Dr. Tezil further advanced his research on aging and small molecules targeting acetyltransferases at the Gladstone Institutes and Buck Institute for Research on Aging in California. Prior to joining Augustine Tx, Dr Tezil led innovative projects in biotech companies such as Dualyx specialized in immunotherapies. Welcome on board! #biotech #newappointment #healthcare #pharmacology

We're #hiring a new Lab technician Pharmacology in Leuven, Flemish Region. Apply today or share this post with your network.

We're #hiring a new Lab Technician Pharmacology in Leuven, Flemish Region. Apply today or share this post with your network.

📣 Augustine Therapeutics is hiring! We are looking for Lab Technician in Pharmacology to join our Discovery team in Leuven. Be part of an exciting journey to advance our unique pipeline of Best-in-Class small molecule HDAC6 inhibitors as potential treatments for neurodegenerative and cardio-metabolism diseases. Apply here: https://lnkd.in/eDTsmB6B #discovery #pharmacology #jobalert #cmt #hdac6 #biotech

📣 Are you eager to discover the latest drug discovery and development efforts in advancing HDAC6 inhibitors as potential treatments for PNS and CNS diseases? 📝 Our Expert Opinion in Therapeutic Targets review article is now online, co-authored with our scientific founder Prof. Ludo Van Den Bosch from the VIB-KU Leuven Center For Brain & Disease Research, and Dr. Robert Prior, both at the Origin of Augustine! Kudos to Frederik Rombouts Jonathan van Eyll Sylvain Celanire! To access the article: https://lnkd.in/d3PwwuDA On the Origins: https://lnkd.in/ezkbryjd #HDAC6 #VIB #drugdiscovery

¡Todo el equipo de Augustine Therapeutics felicita a ASABYS PARTNERS! ¡Bien hecho!

We are pleased to announce that Dr. Baptiste Rugeri will join the Augustine team as Principal Scientist Medicinal Chemistry.  Baptiste holds a PhD from the University of Burgundy in Dijon, France. He started his career at Sygnature Discovery (Nottingham, UK) where he supported various medicinal chemistry programs. Next he joined Domain Therapeutics (Strasbourg, France), where he contributed to two programs that successfully delivered leads to IND-enabling stage, a PAR2 negative allosteric modulator and EP4R antagonist, and later led immuno-oncology GPCR projects.  At Augustine, Baptiste will take up responsibility to advance the periperally restricted and CNS penetrant HDAC6 inhibitor pipeline. Welcome on board!  #team #biotech #newappointment #healthcare #drugdevelopment

Augustine Therapeutics is proud to sponsor the 2024 Global CMT Research Convention, organized by the US CMT Research Foundation, to be held from September 26th to 28th 2024 at the Royal Sonesta Boston, Cambridge, MA. The event is gathering researchers, biotech and pharma companies, investors, and patients to discuss widely the latest research and development towards finding a cure for Charcot-Marie-Tooth patients. This yearly convention enhances the scope and possibilities of research discoveries as a step forward for the people who are living with CMT! In addition, our team will participate to the ‘Researcher Day’ on Friday, September 27th 2024: 🔵 Our Vice President Drug Discovery, Dr. Frederik Rombouts will be speaking at the session “Therapeutic Approaches That Target the Biology of CMT – 10:15 am EDT. Dr. Rombouts will provide an update on our first clinical candidate AGT100216 progressing towards First-in-man studies. AGT100216 is a peripheral-restricted selective, orally bioavailable and safe, non-hydroxamate and non-fluoromethyloxadiazole HDAC6 inhibitor. Title: ‘Developing Best-in-Class HDAC6 Inhibitors for the treatment of CMT1A’ 🔵 Our Executive Chair, Dr. Gerhard Koenig, will be panelist at the session gathering biotech Executive leaders on the theme “Understanding the criteria for pursuing a drug program for CMT” at 5:05 pm EDT. Dr. Koenig will highlight the groundbreaking science foundations of our HDAC6 program that emerged from the lab of Prof. Ludo Van Den Bosch at the VIB-KU Leuven, and the subsequent robust preclinical data in CMT studies that support our recently announced Series A1 round led by Asabys Partners, with the participation of Eli Lilly and Company, the CMT Research Foundation along our historical investors. ➡ Find out details of the event and agenda here: https://lnkd.in/giqRXt2F  #charcotmarietooth #cmtresearch #raredisease #drugdevelopment #healthcareinnovation #HDAC6 #GlobalCMTResearchConvention

We are thrilled to welcome Carl Bjartmar, M.D., Ph.D., as our new Chief Medical Officer! In combination with a successful track record in advancing innovative therapeutic programs for rare diseases within major pharma and biotech organizations, Dr. Bjartmar’s deep expertise in clinical research will support our mission of developing our next-generation, Best-in-Class HDAC6 inhibitors as potential treatments for peripheral and CNS diseases. To learn more about Dr. Bjartmar, read here: https://lnkd.in/eU97wG_e #newappointment #biotech #team #healthcare #innovation #pharma #drugdevelopment